Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell activation, proliferation, and survival, and can induce apoptosis of tumor-specific T cells (Keir et al., 2008; Zhang et al., 2009; Zitvogel and Kroemer, 2012). By inhibiting the PD-1/PD-L1 interaction, Bavencio reduces the ability of the tumor to evade immune system targeting, and enables the activation of T cells and the adaptive immune system (Avelumab fact sheet, 2015; Pardoll, 2012).
In addition, preclinical and clinical studies have suggested that drugs targeting the PD-1/PD-L1 pathway may have fewer side effects than other immune checkpoint inhibitors (Raufi and Klempner, 2015; Brahmer et al., 2012).
- Bavencio: Head and neck cancer
- Bavencio: Ovarian cancer
- Bavencio: Bladder cancer
- avelumab: Renal cell cancer (RCC)
- avelumab: Non-small cell lung cancer (NSCLC)
- avelumab: Gastric cancer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pkfqsh/bavencio_drug?w=4